Search Results - "Pettit, Syril D"

Can non‐clinical repolarization assays predict the results of clinical thorough QT studies? Results from a research consortium by Park, Eunjung, Gintant, Gary A, Bi, Daoqin, Kozeli, Devi, Pettit, Syril D, Pierson, Jennifer B, Skinner, Matthew, Willard, James, Wisialowski, Todd, Koerner, John, Valentin, Jean‐Pierre

“…Background and Purpose Translation of non‐clinical markers of delayed ventricular repolarization to clinical prolongation of the QT interval corrected for…”
Get full text

‘All In’: a pragmatic framework for COVID‐19 testing and action on a global scale by Pettit, Syril D, Jerome, Keith R, Rouquié, David, Mari, Bernard, Barbry, Pascal, Kanda, Yasunari, Matsumoto, Mineo, Hester, Susan, Wehmas, Leah, Botten, Jason W, Bruce, Emily A

“…Current demand for SARS‐CoV‐2 testing is straining material resource and labor capacity around the globe. As a result, the public health and clinical community…”
Get full text

A (not) new Rx: Quality Improvement for NAM by Pettit, Syril D.

“…New Approach Methodologies (NAMs) are a rapidly growing set of tools/methods for use food, drug, consumer product, or chemical safety assessment paradigms. The…”
Get full text

Current challenges in the evaluation of cardiac safety during drug development: Translational medicine meets the Critical Path Initiative by Piccini, Jonathan P., MD, MHS, Whellan, David J., MD, MHS, Berridge, Brian R., DVM, PhD, Finkle, John K., MD, Pettit, Syril D., MEM, Stockbridge, Norman, MD, PhD, Valentin, Jean-Pierre, PhD, Vargas, Hugo M., PhD, Krucoff, Mitchell W., MD

“…In October 2008, in a public forum organized by the Cardiac Safety Research Consortium and the Health and Environmental Sciences Institute, leaders from…”
Get full text

Integrated Genotoxicity Testing of three anti-infective drugs using the TGx-DDI transcriptomic biomarker and high-throughput CometChip ® assay in TK6 cells by Buick, Julie K, Rowan-Carroll, Andrea, Gagné, Rémi, Williams, Andrew, Chen, Renxiang, Li, Heng-Hong, Fornace, Jr, Albert J, Chao, Christy, Engelward, Bevin P, Frötschl, Roland, Ellinger-Ziegelbauer, Heidrun, Pettit, Syril D, Aubrecht, Jiri, Yauk, Carole L

“…Genotoxicity testing relies on the detection of gene mutations and chromosome damage and has been used in the genetic safety assessment of drugs and chemicals…”
Get full text

ToxPoint: Health Disparities, COVID-19, and Owning Our Share by Pettit, Syril D

Get full text

Do current approaches to assessing therapy related adverse events align with the needs of long-term cancer patients and survivors? by Pettit, Syril D, Kirch, Rebecca

“…The increasing efficacy of cancer therapeutics means that the timespan of cancer therapy administration is undergoing a transition to increasingly long-term…”
Get full text

Overview of an Interlaboratory Collaboration on Evaluating the Effects of Model Hepatotoxicants on Hepatic Gene Expression by Ulrich, Roger G., Rockett, John C., Gibson, G. Gordon, Pettit, Syril D.

“…DNA microarrays and related tools offer promise for identification of pathways involved in toxic responses to xenobiotics. To be useful for risk assessment,…”
Get full text

From silos to multilingual science by Pettit, Syril D

Get more information

A Collaborative Initiative to Establish Genomic Biomarkers for Assessing Tumorigenic Potential to Reduce Reliance on Conventional Rodent Carcinogenicity Studies by Corton, J Christopher, Mitchell, Constance A, Auerbach, Scott, Bushel, Pierre, Ellinger-Ziegelbauer, Heidrun, Escobar, Patricia A, Froetschl, Roland, Harrill, Alison H, Johnson, Kamin, Klaunig, James E, Pandiri, Arun R, Podtelezhnikov, Alexei A, Rager, Julia E, Tanis, Keith Q, van der Laan, Jan Willem, Vespa, Alisa, Yauk, Carole L, Pettit, Syril D, Sistare, Frank D

“…Abstract There is growing recognition across broad sectors of the scientific community that use of genomic biomarkers has the potential to reduce the need for…”
Get full text

Overview of the Application of Transcription Profiling Using Selected Nephrotoxicants for Toxicology Assessment by Kramer, Jeffrey A., Pettit, Syril D., Amin, Rupesh P., Bertram, Timothy A., Car, Bruce, Cunningham, Michael, Curtiss, Sandra W., Davis, John W., Kind, Clive, Lawton, Michael, Naciff, Jorge M., Oreffo, Victor, Roman, Richard J., Sistare, Frank D., Stevens, James, Thompson, Karol, Vickers, Alison E., Wild, Stacey, Afshari, Cynthia A.

“…Microarrays allow for the simultaneous measurement of changes in the levels of thousands of messenger RNAs within a single experiment. As such, the potential…”
Get full text

Stakeholder perspectives on addressing adverse events from adjuvant cancer therapy: A qualitative study by Pettit, Syril D., Silberman, Pamela, Hassmiller Lich, Kristen, Kirch, Rebecca A., Lipshultz, Steven E., Teal, Randall, Basch, Ethan

“…Background With increasing survival rates, a growing population of patients with cancer have received or will receive adjuvant therapy to prevent cancer…”
Get full text

Enhancing quality of life as a goal for anticancer therapeutics by Pettit, Syril D, Lipshultz, Steven E, Cleeland, Charles S, Roberts, Samantha, Davis, Myrtle, Berridge, Brian R, Kirch, Rebecca A

“…Translational cancer research requires a quality-of-life-driven agenda…”
Get more information

Toxicogenomics in Risk Assessment: An Overview of an HESI Collaborative Research Program by Pennie, William, Pettit, Syril D., Lord, Peter G.

“…The value of genomic approaches in hypothesis generation is being realized as a tool for understanding toxicity and consequently contributing to an assessment…”
Get full text

Current Practices in Preclinical Drug Development: Gaps in Hemostasis Testing to Assess Risk of Thromboembolic Injury by Schultze, A. Eric, Walker, Dana B., Turk, James R., Tarrant, Jacqueline M., Brooks, Marjory B., Pettit, Syril D.

“…The Health and Environmental Sciences Institute Cardiac Biomarkers Working Group surveyed the pharmaceutical development community to investigate practices in…”
Get full text

What do we need to know prior to thinking about incorporating an epigenetic evaluation into safety assessments? by Goodman, Jay I, Augustine, Karen A, Cunnningham, Michael L, Dixon, Darlene, Dragan, Yvonne P, Falls, James Greg, Rasoulpour, Reza J, Sills, Robert C, Storer, Richard D, Wolf, Douglas C, Pettit, Syril D

“…The International Life Sciences Institute, Health and Environmental Sciences Institute sponsored a workshop entitled "State of the Science: Evaluating…”
Get full text

A public–private consortium advances cardiac safety evaluation: Achievements of the HESI Cardiac Safety Technical Committee by Pierson, Jennifer B., Berridge, Brian R., Brooks, Marjory B., Dreher, Kevin, Koerner, John, Schultze, A. Eric, Sarazan, R. Dustan, Valentin, Jean-Pierre, Vargas, Hugo M., Pettit, Syril D.

“…Introduction: The evaluation of cardiovascular side-effects is a critical element in the development of all new drugs and chemicals. Cardiac safety issues are…”
Get full text

A HESI consortium approach to assess the human predictive value of non-clinical repolarization assays by Trepakova, Elena S., Koerner, John, Pettit, Syril D., Valentin, Jean-Pierre

“…Drug-induced ventricular arrhythmia and Torsades de Pointes remain a serious public health issues in bringing safe new pharmaceuticals to the market place…”
Get full text

Opportunities to meet clinical cardio-oncology needs with new approaches to non-clinical safety assessment by Berridge, Brian R, Pettit, Syril D, Sarazan, R. Dustan

“…Abstract Marked successes in treating a wide variety of malignancies in both adults and children have raised concerns about the cardiotoxic sequelae of several…”
Get full text

Integrated and translational nonclinical in vivo cardiovascular risk assessment: Gaps and opportunities by Berridge, Brian R., Hoffmann, Peter, Turk, James R., Sellke, Frank, Gintant, Gary, Hirkaler, Gerald, Dreher, Kevin, Schultze, A. Eric, Walker, Dana, Edmunds, Nick, Halpern, Wendy, Falls, James, Sanders, Marty, Pettit, Syril D.

“…► Nonclinical CV safety testing paradigms may not adequately model complex patient populations. ► Holistic and predictive approach needed to understand long…”
Get full text